These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 26535485)

  • 1. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.
    Coinu A; Petrelli F; Barni S
    Expert Rev Anticancer Ther; 2016; 16(1):33-43. PubMed ID: 26535485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temsirolimus for advanced renal cell carcinoma.
    Bergmann L; Maute L; Guschmann M
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
    Barthélémy P; Hoch B; Chevreau C; Joly F; Laguerre B; Lokiec F; Duclos B
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):42-56. PubMed ID: 23523056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal management of metastatic renal cell carcinoma: current status.
    Escudier B; Albiges L; Sonpavde G
    Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of mTor inhibitors for renal cancer.
    Ghidini M; Petrelli F; Ghidini A; Tomasello G; Hahne JC; Passalacqua R; Barni S
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1229-1237. PubMed ID: 28952411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiating mTOR inhibitors in renal cell carcinoma.
    Pal SK; Quinn DI
    Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging tyrosine kinase inhibitors for the treatment of renal cancer.
    Iacovelli R; Albiges L; Escudier B
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):379-92. PubMed ID: 25982181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line systemic therapy for the treatment of metastatic renal cell cancer.
    Kruck S; Bedke J; Kuczyk MA; Merseburger AS
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):777-85. PubMed ID: 22716494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
    Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
    Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
    Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
    Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temsirolimus: a safety and efficacy review.
    Bukowski RM
    Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
    Tang PA; Vickers MM; Heng DY
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma.
    Stenner-Liewen F; Grünwald V; Greil R; Porta C
    Expert Rev Anticancer Ther; 2013 Sep; 13(9):1021-33. PubMed ID: 24024788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel tyrosine kinase inhibitors for renal cell carcinoma.
    Dorff TB; Pal SK; Quinn DI
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):67-73. PubMed ID: 24308791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tivozanib: a new treatment option for renal cell carcinoma.
    Saes L; Eskens FALM
    Drugs Today (Barc); 2017 Nov; 53(11):609-618. PubMed ID: 29451277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges.
    González-Larriba JL; Maroto P; Durán I; Lambea J; Flores L; Castellano D;
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):217-226. PubMed ID: 28105863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
    Alimohamed N; Lee JL; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Tantravahi S; Kollmannsberger C; North S; Rini BI; Choueiri TK; Heng DY
    Clin Genitourin Cancer; 2014 Aug; 12(4):e127-31. PubMed ID: 24485801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence.
    Tonini G; Fratto ME; Imperatori M; Pantano F; Vincenzi B; Santini D
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):921-30. PubMed ID: 21707289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.